We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Novel Imaging Technology Developed to Study Sudden Cardiac Arrest

By HospiMedica International staff writers
Posted on 21 Nov 2009
A research team has developed an innovative optical system to simultaneously image electrical activity and metabolic properties in the same region of a heart, to study the complex mechanisms that lead to sudden cardiac arrest. More...
Evaluated in animal models, the system could dramatically further scientists' understanding of the relationship between metabolic disorders and heart rhythm disturbances in humans that can lead to cardiac arrest and death, and provide a platform for testing new treatments to prevent or stop potentially fatal irregular heartbeats, known as arrhythmias.

The design and use of the dual camera system is described in the November 1, 2009, issue of the journal Experimental Biology and Medicine by researchers from Vanderbilt University (Nashville, TN,USA). "The challenge in understanding cardiac rhythm disorders is to discern the dynamic relationship between multiple cardiac variables,” said one of the coauthors of the study and the project's lead investigator, John P. Wikswo, Ph.D., a Vanderbilt professor and Vanderbilt Institute for Integrative Biosystems Research and Education (VIIBRE) director. "This dual camera system opens up a new window for correlating metabolic and electrophysiological events, which are usually studied independently.”

The 11-year-old research project would have been terminated this year due to lack of funding, according to Dr. Wikswo. However, a US$566,000 American Recovery and Reinvestment Act grant from the U.S. national Heart Lung and blood Institute (NHLBI; Bethesda, MD, USA) is enabling the 13-member research team to continue developing and testing the innovative optical system. Recovery Act funds are also allowing the team to purchase a pair of $60,000 high-speed and highly sensitive digital cameras to record the changes in the metabolic and electrical activity of isolated cardiac tissue using low-intensity fluorescent dyes under conditions associated with heart failure, ischemia, fibrillation and other pathological circumstances.

"Through the Recovery Act, the NHLBI is able to support promising research to develop and enhance innovative technologies to help us better understand the complex mechanisms involved in potentially fatal conditions such as sudden cardiac arrest,” said NHLBI director Elizabeth G. Nabel, M.D. "This research will allow us to better understand how to prevent and treat life-threatening cardiac rhythm disturbances and potentially save thousands of lives every year.”

Each year, 250,000 to 450,000 people die in the United States because of sudden cardiac arrest, a condition that is triggered by arrhythmia. Typically, a complicated series of electrical and metabolic changes precede sudden cardiac arrest.

The Vanderbilt researchers devised and assessed a novel way to visualize the electrical activity of the heart in relation to its structure and changing metabolic state under different pathologic conditions. Their multimodal cardiac imaging technique uses a two-camera approach to integrate electrophysiologic imaging with optical fluorescence imaging of metabolic activity associated with damaged heart tissue and tachycardia, or accelerated heart rate. The biochemical and electrochemical studies of heart tissue under controlled conditions will enhance investigators' understanding of electrometabolic cardiac disorders and their clinical treatment.

The advantages of this imaging system over others include rapid setup, two-color image separation, high spatial resolution, and an optional software camera-calibration routine that eliminates the need for precise camera alignment. In the article, the scientists provided a detailed description of a camera calibration procedure along with multiple examples.

Moreover, the multimodal imaging system will be a less-invasive, instrumental tool in helping scientists discover and test safe and effective ways to prevent or treat arrhythmias. Current treatments include medications that can produce undesirable side effects, and the implantable cardioverter defibrillator, which is a small device placed under the skin in the chest and uses electrical pulses or shocks to help control life-threatening arrhythmias.

Related Links:
Vanderbilt University





Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.